Original ArticleNon–Small Cell Lung CancerExamining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Non–Small Cell Lung Cancer
Under a Creative Commons license
open access
Keywords
NSCLC
Erlotinib
EGFR mutations
Uncommon
Rare
Cited by (0)
Disclosure: Drs. Delmar, Klughmammer, Shames, and Wu are employees of F. Hoffmann-La Roche and own stock in F. Hoffmann-La Roche. Drs. Klingelschmitt, Spleiss, and Yue are employees of F. Hoffmann-La Roche. Dr. Ciuleanu has recieved an honorarium from F. Hoffmann-La Roche. Dr. Mok has consulted for and recieved honoraria for symposia and advisory boards for F. Hoffmann-La Roche. Dr. Reck has served as an advisor for F. Hoffmann-La Roche.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.